Why weight loss is excluded
When Medicare's prescription drug benefit (Part D) was created, the statute specifically excluded “agents when used for anorexia, weight loss, or weight gain” from coverage — language mirroring a long-standing Medicaid rule. That exclusion still stands, which is why Medicare won't pay for Ozempic, Wegovy, or Zepbound when the reason is weight loss, no matter how medically beneficial. It's a statutory rule (it takes an act of Congress or a demonstration like the Bridge to change), not a plan-by-plan choice — and it applies to Medicare Advantage too.
The coverage matrix: drug × use
Whether Medicare covers your GLP-1 depends entirely on the reason you're taking it:
| Drug | Covered for… | Weight loss? |
|---|---|---|
| Ozempic | Type 2 diabetes (+ CV/kidney in diabetes) | No |
| Mounjaro | Type 2 diabetes | No |
| Wegovy | Cardiovascular risk reduction (heart disease + obesity) | No — except via the Bridge |
| Zepbound | Obstructive sleep apnea (in obesity) | No — except via the Bridge |
| Rybelsus | Type 2 diabetes | No |
What Medicare does cover (with documentation)
Ozempic for type 2 diabetes
Covered under Part D for diabetes (and its CV/kidney indications in diabetes), subject to your plan's formulary and prior authorization.
Wegovy for cardiovascular risk
Because Wegovy is FDA-approved to reduce heart attack/stroke risk in people with established heart disease and overweight/obesity, Part D can cover it for that indication.
Zepbound for sleep apnea
Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea, a non-weight-loss indication Medicare can cover with documentation (typically a sleep study).
Any of them for weight loss alone
Not covered outside the Bridge — the statutory weight-loss exclusion applies, even with obesity.
Common scenarios
You have type 2 diabetes
Ozempic (or Mounjaro) is covered for diabetes with a prior authorization — use that, and you get the weight benefit alongside glucose control.
You have heart disease + obesity, no diabetes
Wegovy may be covered for cardiovascular risk reduction — ask your provider to pursue that indication.
You have obesity + sleep apnea
Zepbound may be covered for OSA (with a sleep study) — and it also treats the weight.
You have obesity, no qualifying condition
Check the Medicare GLP-1 Bridge ($50/mo) — if you meet the BMI-based criteria, it's your best path; otherwise, cash-pay.
The new $50/month Bridge
The Medicare GLP-1 Bridge pilot (July 2026 – December 2027) offers a flat $50/monthcopay for Wegovy, the Zepbound KwikPen, or Foundayo to eligible members — the first time Medicare helps pay for weight-loss GLP-1s. It doesn't cover Ozempic or Mounjaro. Eligibility is based on BMI and health conditions (BMI ≥35; or ≥30 with certain conditions; or ≥27 with cardiovascular risk factors).
If none of these fit: cash-pay
Cash-pay options — manufacturer self-pay and the federal TrumpRx portal — put GLP-1s in the ~$149–$350/month range, far below retail. And if you were denied for a covered indication you believe you qualify for, you can appeal. Compare every path on cheapest GLP-1.
Coverage depends on your specific plan and documented diagnosis. This summarizes federal rules as of 2026-07-18 — confirm with Medicare and your Part D plan. Educational only, not medical or insurance advice.